Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study
Authors:
- Yuko KanekoYKYuko Kaneko
- Takahiro NunokawaTNTakahiro Nunokawa
- Yoshinori TaniguchiYTYoshinori Taniguchi
- Yukie YamaguchiYYYukie Yamaguchi
- Takahisa GonoTGTakahisa Gono
- Kenichi MasuiKMKenichi Masui
- Atsushi KawakamiAKAtsushi Kawakami
- Yasushi KawaguchiYKYasushi Kawaguchi
- Shinji SatoSSShinji Sato
- Masataka KuwanaMKMasataka Kuwana
- JAMI investigatorsJIJAMI investigators
- Yutaka OkanoYOYutaka Okano
Open Access
- 25 June 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (1) , 112-119
Abstract
Objective: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). Methods: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. Results: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation–associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). Conclusion: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.Keywords
Funding Information
- Astellas
This publication has 28 references indexed in Scilit:
- Meta-analysis of the association of dermatomyositis and polymyositis with cancerBritish Journal of Dermatology, 2013
- Deciphering the Clinical Presentations, Pathogenesis, and Treatment of the Idiopathic Inflammatory MyopathiesJAMA, 2011
- Cancer-Associated Myositis: Clinical Features and Prognostic SignsAnnals of the New York Academy of Sciences, 2005
- Risk of cancer in patients with dermatomyositis or polymyositis and follow-up implications: a Scottish population-based cohort studyBritish Journal of Cancer, 2001
- Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy: A Population-Based Cohort StudyAnnals of Internal Medicine, 2001
- Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based studyThe Lancet, 2001
- High incidence of malignancies in patients with dermatomyositis and polymyositis: An 11-year analysisSeminars in Arthritis and Rheumatism, 1998
- Risk of Cancer in Patients with Dermatomyositis or PolymyositisNew England Journal of Medicine, 1992
- Dermatomyositis and MalignancyAnnals of Internal Medicine, 1976
- Polymyositis and DermatomyositisNew England Journal of Medicine, 1975